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Reply to Eisen and McBryde
TO THE EDITOR—Eisen and McBryde [1]
support the conclusion of our experimen-
tal study on antiplatelet prophylaxis of
experimental infective endocarditis (IE)
and the need to further investigate new
drugs of the anti-GPIIb/IIIa receptor
class (eg, abciximab) that could be given
orally. Their argument is based on both
the greater ability of abciximab than
more classic aspirin-plus-ticlopidine regi-
men to prevent experimental IE caused
by both streptococci and staphylococci,
and on their meta-analysis showing that
classical antiplatelet therapy given in es-
tablished IE provided a beneﬁt in terms
of embolus prevention, which was coun-
terbalanced by a risk of increased overall
mortality. Thus, there is a proof of con-
cept for a beneﬁt of antiplatelet regimens
in both IE prevention and therapy, but
improved drugs and drug formulations
must be sought.
We support the argument of Eisen and
McBryde that further development on
anti-GPIIb/IIIa drugs could represent an
improvement for IE prevention in select-
ed at-risk patients. However, we would
not entirely discard a potential beneﬁt
from more classical antiplatelet regimens,
as they did show a signiﬁcant protective
effect against experimental IE caused by
both Streptococcus gordonii and Staphylo-
coccus aureus experimental IE, although
abciximab was more effective.
Eisen and McBryde’s arguments are
based on the relatively limited (although
not null) efﬁcacy of classical antiplatelet
regimens (mainly aspirin) to prevent em-
bolism in established IE. They also em-
phasize that antiaggregant therapy should
be given before the onset of IE rather than
after IE establishment. Indeed, early anti-
aggregant therapy may decrease the size
of nascent vegetations and impede their
further enlargement, whereas late antiag-
gregant therapy might favor vegetation
dislodgment and bleeding in embolized
areas [2].
The fact that antiaggregant given be-
fore IE is not a risk factor for increased
embolism in case of later IE development
is critical, as it does not prohibit antiag-
gregants as a prophylactic measure in
at-risk patients, at least with classical
drugs. The question, however, is whether
or not chronic use of aspirin or other an-
tiplatelet drugs might protect patients
from IE development.We sought to deter-
mine whether existing human data could
providesomecluestoanswer thisquestion.
Unfortunately, neither the Framingham
Heart Study cohort nor the International
Collaboration on Endocarditis database
could provide deﬁnitive information on
thisspeciﬁc issue.Therefore,wearecurrently
planning a prospective observational study
in patients with bioprosthetic heart valves
receiving or not receiving thrombosis pro-
phylaxis with antiplatelet drugs.
We also would like to emphasize the
protective effect of the new-generation
thrombin inhibitor dabigatran against S.
aureus experimental IE. Control aceno-
coumarol did not protect against either
streptococcal or staphylococcal experi-
mental IE, whereas dabigatran speciﬁ-
cally protected against S. aureus IE. This
is likely associated with the observation
that dabigatran inhibits not only thrombin,
but also the S. aureus coagulase, which can
bypass thrombin and polymerize ﬁbrino-
gen into ﬁbrin, even in acenocoumarol-
or citrate-anticoagulated blood. The dual
anticoagulant and anti–S. aureus activity
of dabigatran would be ideal in patients
with prosthetic valves, in whom S. aureus
IE is lethal in close to 50% of cases [3, 4].
Unfortunately, dabigatran did not do well
in such patients [5, 6].While further phar-
macologic development is required before
dabigatran can be used in prosthetic valves,
it opens yet another strategy for S. aureus
IE prevention.
We agree with Eisen and McBryde that
more developments are needed regarding
the prevention and treatment of IE. Re-
garding prevention, we have abandoned
antibiotic prophylaxis overkill, which
was based on intuitive rather than evi-
dence-based medicine [7, 8]. Yet, IE is a
persistent Damocles sword in at-risk pa-
tients, as it can happen at any time during
their life. Simple alternatives are needed
for these patients, and chronic use of
antiplatelet drugs could be one of them.
Regarding therapy, 2–6 week courses of
parenteral antibiotics are still the standard.
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We think that numerous improvements
are possible, including adjunctive therapy
that could interfere with vegetation devel-
opment, promote its resolution, and help
bacterial clearance. Indeed, while further
improvements in antiaggregant drugs
seem a promising approach, other innova-
tive options must also be considered, such
as decreasing embolic events in patients
suffering IE and chronically treated with
statins [9], where pleomorphic activity
might reveal as yet unexpected beneﬁts.
New imaginative strategies are welcome
to solve the IE problem.
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